At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
TILT-123biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients With Injectable Solid Tumors
In Brief
A Phase 1 clinical trial evaluating TILT-123 for Solid Tumor. Completed, enrolled 32 participants across 2 sites.
Detailed Summary
This is an open-label, phase 1, dose-escalation, multicenter trial evaluating the safety of oncolytic adenovirus TILT-123 as monotherapy in advanced solid tumor patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesFinland
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJan 2021
Primary CompletionSep 2025
TodayJul 2026
First PostedJan 5, 2021
Enrollment StartJan 11, 2021
Primary CompletionSep 3, 2025
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 5.5 years ago
Interventions
TILT-123biological
TNFalpha and IL-2 coding oncolytic adenovirus TILT-123